QuantuMDx has announced that Neil Butler has joined its Board as an Independent Non-Executive Director.
Neil is a seasoned healthcare executive with over 20 years’ experience working in, and managing, global medical diagnostic companies involved in the development of point-of-care IVD medical devices. Throughout his career, Neil has held various senior management roles including Founding Chief Executive Officer of three diagnostic businesses, Oxford Biosensors, Vivacta and Spectromics. Neil currently serves on the Board of Nidor Dx, Radisens and Spectromics and previously served as Chair and Non-Executive Director for Atlas Genetics / Binx Health and Genomic Vision. Neil is also a Strategic Advisory Team member for the Engineering and Physical Sciences Research Council and has previously carried out due diligence for several European and US VC’s on diagnostic related investments.
Professor Sir John Burn, Chair of QuantuMDx Group said: “We are delighted to have attracted someone of Neil’s calibre to the Board of QuantuMDx. His skill set and his expertise, particularly within IVD companies, will be invaluable to us as we progress towards full commercialisation of our Q-POC™ molecular diagnostic device and portfolio of tests as well as deliver on the wider value of our technology platforms.”
Commenting on his appointment, Neil Butler, Non-Executive Director of QuantuMDx said: “I have been aware of QuantuMDx and the work they have been doing for some time and so it was a great pleasure to accept this position on its Board. There is a significant need, in a range of healthcare settings, for a rapid, affordable and accurate point-of-care device with high multiplexing capabilities; Q-POC™ provides this solution. I am looking forward to working with the management team and the Board to continue its development and bring the device to market and to the communities who will benefit from it, as quickly as possible.”
About QuantuMDx Group
QuantuMDx Group is a multinational company with a global vision: to revolutionise healthcare and help eradicate disease by making accurate diagnostics universally accessible.
Our flagship device, the Q-POC™, compresses a molecular diagnostics laboratory into a simple-to-use, portable, affordable device. It can be used anywhere from remote rural settings to clinics and hospitals, providing results within 30 minutes.
Headquartered in the UK, QuantuMDx has operations and global partnerships with healthcare providers in the United States, Asia, Europe and Africa – keeping us at the forefront of molecular diagnostics.
For media enquiries:
Debra Daglish, Marketing Communications Manager, QuantuMDx Group